Horm Metab Res 2005; 37(2): 59-62
DOI: 10.1055/s-2005-861157
© Georg Thieme Verlag KG Stuttgart · New York

RNA Interference-based Strategies for Metabolic Syndrome Treatment

A.  Barthel1 , S.  Herzig2 , H.-W.  Müller3 , J.  Harborth4 , S.  R.  Bornstein5
  • 1Department of Endocrinology, Diabetes and Rheumatology, University Hospital Duesseldorf, Germany
  • 2Department Molecular Metabolic Control, German Cancer Research Center, Heidelberg, Germany
  • 3Department of Nuclear Medicine, University Hospital Duesseldorf, Germany
  • 4Alnylam Pharmaceuticals, Cambridge, MA, USA
  • 5Department of Medicine, University of Dresden, Carl Gustav Carus, Dresden, Germany
Further Information

Publication History

Received 4 January 2005

Accepted after revision 4 January 2005

Publication Date:
21 March 2005 (online)


RNA interference is a naturally occurring cellular mechanism to inhibit the expression of specific gene products. The technical application of RNA interference offers great potential for the specific treatment of a huge variety of diseases including the metabolic syndrome, one of the most challenging threats to human health associated with our civilization. In order to develop novel and powerful strategies for the treatment of the metabolic syndrome, it is essential to define a set of specific gene products that may be targeted by RNA interference. Based on currently available in vitro and in vivo data, we discuss the feasibility of candidate genes involved in the pathophysiology of the metabolic syndrome as potential targets for a rational RNA interference based therapy in this review.


Dr. Andreas Barthel

Department of Endocrinology, Diabetology and Rheumatology, University Hospital Duesseldorf

Moorenstr. 5 · 40225 Düsseldorf · Germany

Phone: +49(211)811-78 10

Fax: +49(211)811-78 60

Email: Andreas.Barthel@uni-duesseldorf.de